NantHealth, a transformational healthcare company converging science and technology through a single integrated clinical platform, will unveil the industry's first, open Clinical Operating System (cOS) for value-based, coordinated care at this year's NHS Confederation Annual Conference and Exhibition. cOS is an intelligent cloud-based platform integrating clinical, financial, operational and environmental data that's empowering clinicians, providers, patients, commissioners, social care workers and researchers to transcend the traditional barriers of today's healthcare system and allow health and social care integration to be truly realised.
"NantHealth's mission is to solve the chief problems plaguing our healthcare system, which is the lack of truly personalised, coordinated and pro-active care models that connect patients and their care providers," said Dr Patrick Soon-Shiong, MD, NantHealth's founder and the pioneer of pharmaceutical treatments for both diabetes and cancer. "Our most important industry, healthcare, is fragmented and lags all other industries in its ability to integrate services and rapidly introduce new practice. cOS is the first viable, proven platform for making complex information such as someone's genomic profile as simple as their heart rate and blood pressure. Our ability to design, automate and deliver new models and systems of care is critical for advancing 21st century medicine, and for the first time, is now possible."
An open, standards-based technology platform, cOS integrates data from existing legacy systems, such as electronic patient records (EPR), patient administration systems (PAS) from multiple platforms, imaging, GP systems, diagnostics, research, medical device data, patient level costing and service-line reporting, in real-time, to enable care that is personalised, coordinated and proactive. When cOS capabilities are combined with NantHealth's applications such as advanced molecular diagnostics and care coordination applications, informed decisions can be made in seconds, and patients matched to the right treatment protocols - ultimately saving lives and reducing cost of delivery. Health and care delivery becomes transformative for both care givers and the people they serve.
NantHealth cOS is the centrepiece of a $1 billion investment by Dr. Soon-Shiong, who has brought together some of the most innovative companies and solutions in biotechnology and healthcare IT with the goal of providing the right care, at the right time, in the right place and at the lowest cost. He has pioneered treatments for both diabetes and cancer, published more than 100 scientific papers, and holds over 95 issued patents on ground-breaking advancements across myriad fields. Dr. Soon-Shiong performed the world's first encapsulated human islet transplant and the first pig to man islet cell transplant in diabetic patients and invented and developed Abraxane, the first US government approved injectable drug using human protein nanoparticle delivery technology in the treatment of breast, lung and pancreatic cancer. Dr. Soon-Shiong is the founder of two multi-billion dollar pharmaceutical companies.
NantHealth cOS will be on display along with NantHealth's full line of transformational healthcare solutions at NHS Confederation Annual Conference and Exhibition, 4-7 June, at the ACC Liverpool.
Studies link gut dysbiosis to pancreatic cancer, offering pathways for early detection